Navigation Links
Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
Date:4/17/2008

Tepha Corporate Partners, Aesculap and Tornier, Conduct Clinical

Evaluations of TephaFLEX(R) Suture Products

LEXINGTON, Mass., April 17 /PRNewswire/ -- Tepha, Inc., a developer of medical devices derived from a new class of polymers, announced today that two of its corporate partners, Aesculap and Tornier, are conducting initial clinical evaluations of the Company's new TephaFLEX(R) suture products. These clinical evaluations, conducted in both the United States and Europe, represent the first human usage of medical devices derived from Tepha's new class of resorbable polymers called polyhydroxyalkanoates ("PHA's"). The Tepha PHA polymer family is a product of the Company's patented recombinant DNA technology which allows the engineering of resorbable medical devices with mechanical and biologic properties that are matched to specific tissue repair and replacement applications. TephaFLEX(R) monofilament suture is up to 30% stronger, more flexible, and has longer strength retention than currently marketed resorbable sutures.

Dr. Simon Williams, President and CEO of Tepha, commented, "The first human usage of a medical device based on our proprietary polymer technology is an important milestone in Tepha's history. We are grateful for the support of such capable and committed partners as Aesculap and Tornier, and we look forward to these collaborations progressing to the successful commercialization of TephaFLEX(R) suture products."

Aesculap AG, a Tepha corporate partner since 2004, currently is conducting a European trial evaluating suture products based on TephaFLEX(R) fiber in 150 patients undergoing abdominal wall repair procedures. The results of this trial will be submitted to European regulatory authorities to support Aesculap's application for CE Mark approval. Based in Germany, Aesculap is a division of B. Braun Melsungen AG, focused on products for core processes in operative medicine. Aesculap's product range i
'/>"/>

SOURCE Tepha, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...NEY,Nov.25/PRNewswire-FirstCall/--HeartWareInterna...orandprovideroflessinvasive,miniaturizedcirculator...dvancedheartfailure,todayannouncedthatitisschedule...affrayHealthCareConferenceat8:00amESTonWednesday,D...PalaceHotel,December1-2. ,, AlivewebcastoftheCo...
(Date:11/24/2009)...wswire/-- ,, WHAT:RomHoubens,aBelgianmanthought...wasactuallyfullyconsciousandawakeduringthattimeand...oxEyeMaxwasfeaturedinthesegmenttoillustratehowpeop...communication. ,, WHEN:GoodMorningAmerica-- Tue...ch.com ,, WHO:RomHoubenswasanengineeringstu...
(Date:11/24/2009)...PRNewswire-FirstCall/--Vermillion,Inc.(VRML)(PinkS...anizationandDisclosureStatementtoday,November24,20...tofDelaware.AhearingtoconsiderapprovaloftheDisclos...withthehearingontheconfirmationofthePlanscheduledf...payallclaimsinfull.ThePlanisexpected,ifapproved,to...
Breaking Medicine Technology:DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Vermillion Files Plan of Reorganization 2Vermillion Files Plan of Reorganization 3Scientists pinpoint protein link to fat storage 9969 1Siemens Donation of Digital Radiography System Benefits Childrens Health Fund 57526 1Siemens Donation of Digital Radiography System Benefits Childrens Health Fund 57526 2Siemens Donation of Digital Radiography System Benefits Childrens Health Fund 57526 3Siemens Donation of Digital Radiography System Benefits Childrens Health Fund 57526 4Community Health Centers and Western Governors University Partner to Address RN Shortage 57522 1Community Health Centers and Western Governors University Partner to Address RN Shortage 57522 2Community Health Centers and Western Governors University Partner to Address RN Shortage 57522 3Community Health Centers and Western Governors University Partner to Address RN Shortage 57522 4
...ificantly Improved Key PSG Parameters of Sleep Mai...tudy Ongoing -, SAN DIEGO, June 12 Arena Pharmac...t Dr. Thomas Roth of Henry Ford,Hospital presented...l of,APD125 for the treatment of insomnia in an or...ing of the Associated Professional Sleep Societies...
...GAITHERSBURG, Md., June 12 ,Micromet, Inc. (Nasdaq...irst,patient has started treatment in a multi-cent...ng BiTE(R) antibody blinatumomab (MT103/MEDI-538) ...a (ALL). Blinatumomab is a T,cell engaging antibod...sed,on B cells. The clinical development program f...
Other Medicine Technology:Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 2Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 3Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 4Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 5Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 6Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 2Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 3Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 4Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 5Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 6
(Date:11/25/2009)...,, KANSASCITY,Mo.,Nov.25/PRNewswire/--TheBartle...,slargestmedicalcliniconDec.9-10,whenKansasCityhos...edpeople. ,, "Thisfreecliniceventhasthepotentia...ysinsteadofjustoneandbeheldonweekdaysinsteadofover...tyFreeHealthClinicandpresidentoftheNationalAssocia...
(Date:11/25/2009)...,, SILVERSPRING,Md.,Nov.25/PRNewswire-USNewswir...,sCenterforDrugEvaluationandResearch,titled"ADiffi...ppearsintheNov.26,2009issueofTheNewEnglandJournalo...-bin/prnh/20090824/FDALOGO ) ,, Inthearticle,Wo...cesstopainmedicationforthosewhoneeditandmanagingth...
(Date:11/25/2009)...Researchers have found evidence of a statistically...fen among patients whose estrogen receptor (ER)-po...f ER-alpha; at serine-118 (ER-alpha S118-P), accor...ember 25 in the Journal of the National Cancer In...as are resistant to tamoxifen. Preclinical studies...
(Date:11/25/2009)... Evaluation and treatment c... Woodstock (Vocus) November 25, 2009 -- C...nasal vaccines and H1N1 vaccine shots at four Cent...another shipment of vaccine has arrived. The clini... Lake and McHenry and will be open as follows: , ...
(Date:11/25/2009)...,, ARLINGTON,Va.,Nov.25/PRNewswire-USNewswire/-...reventHealthCareFraudActof2009,"S.2128,whichisdesi...letopreventfraudinMedicare.ThebillwasintroducedbyS...ainsseveralprovisionstheAmericanAssociationforHome...htheAssociationproposedtoCongressinFebruary.Thosep...
Breaking Medicine News(10 mins):Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
...culture had found out a soluble ingredient which w...sorption of the fat at a healthier level. Another ...luble cellulose, reduces the probability of develo... as the one that adds texture. The use of this ing...
...ation (WHO) the apex medical body warns the people... avian influenza or bird flu virus in the area. I... to provide full information to WHO regarding new ... complete the ongoing assessment of the nature of ...
... by Teva Pharmaceutical Industries Ltd. is said to...disease. According to the latest investigatio... physical abilities of patients suffering from Par...ease the extent of motor activities for the patien...
...ription could be used to avoid medical mistakes, b...// may lead to even more errors. It is known th...0,000 people in hospitals each year. One way hospi...ms may actually be leading to more mistakes. Th...
...ther antihypertensive strategies that use calcium ...r to older treatments with beta-blockers and diure... calcium channel blocker amlodipine with or withou... was prematurely stopped after concerns arose that...
...the most common form of brain cancer might fare be...motherapy than radiotherapy alone . Based on fi...ith the type of cancer known as glioblastoma recei...as who were randomized to receive either radiother...
Other Medicine News:
AST (SGOT) Reagent (Colorimetric, Endpoint Procedure)
AST-GOT
...-line worker" for routine staining protocols frequ...s. It automatically stains big quantities of slide...of reagent stations in combination with a continuo...p to 12 baskets with 30 slides each can be process...
MS/DS 50/100 Slide Stainer
Medicine Products: